Maxim Group initiated coverage on Anixa Biosciences with a new price target
$ANIX
Biotechnology: Pharmaceutical Preparations
Health Care
Maxim Group initiated coverage of Anixa Biosciences with a rating of Buy and set a new price target of $10.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/21/2025 | $10.00 | Buy | Maxim Group |
| 12/23/2022 | $8.00 | Buy | Chardan Capital Markets |
Maxim Group initiated coverage of Anixa Biosciences with a rating of Buy and set a new price target of $10.00
Chardan Capital Markets initiated coverage of Anixa Biosciences with a rating of Buy and set a new price target of $8.00
HC Wainwright & Co. initiated coverage of Anixa Biosciences with a rating of Buy and set a new price target of $11.00
4 - Anixa Biosciences Inc (0000715446) (Issuer)
4 - Anixa Biosciences Inc (0000715446) (Issuer)
4 - Anixa Biosciences Inc (0000715446) (Issuer)
4 - Anixa Biosciences Inc (0000715446) (Issuer)
4 - Anixa Biosciences Inc (0000715446) (Issuer)
4 - Anixa Biosciences Inc (0000715446) (Issuer)
Phase 1 Data Highlights Potential of First-in-Class Vaccine to Transform Breast Cancer Treatment and Prevention Comprehensive Results, Supported by U.S. Department of Defense Funding, to Inform FDA Discussions and Advance Phase 2 Development Plans SAN JOSE, Calif., Sept. 22, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that final results from the Phase 1 clinical trial of its breast cancer vaccine will be presented at the 2025 San Antonio Breast Cancer Symposium (SABCS) on Thursday, December 11, 2025.
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Sept. 16, 2025 /PRNewswire/ -- USA News Group News Commentary – The FDA's accelerated approval of two oncology treatments in August 2025[1] signaled the recent wave of regulatory momentum behind next-generation therapies. Meanwhile, advanced treatment platforms are achieving complete tumor elimination in clinical trials across multiple cancer types[2]. These developments position Oncolytics Biotech Inc. (NASDAQ:ONCY), Anixa Biosciences, Inc. (NASDAQ:ANIX), IceCure Medical Ltd. (NASDAQ:ICCM), ImmunityBio, Inc. (NASDAQ:IBRX), and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Industry analysts at Exactitude Consultancy project the can
Continue to observe a positive safety profile—no dose limiting toxicities, cytokine release syndrome or immune effector cell-associated neurotoxicity SAN JOSE, Calif., Sept. 8, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced it has completed dosing of the fourth cohort in its ongoing Phase 1 clinical trial (ClinicalTrials.gov NCT05316129) evaluating its novel FSHR-targeted CAR-T/CER-T therapy for recurrent ovarian cancer. The study is being conducted through a research partnership with Moffitt Cancer Center ("Moffitt"). The fifth cohort is expected to commence fol
EFFECT - Anixa Biosciences Inc (0000715446) (Filer)
S-3 - Anixa Biosciences Inc (0000715446) (Filer)
10-Q - Anixa Biosciences Inc (0000715446) (Filer)
SAN JOSE, Calif., Oct. 7, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced the appointment of Suyasha Gupta as Senior Director of Clinical Development. In this role, Ms. Gupta will work closely with Dr. Pamela Garzone, Chief Development Officer, to oversee the Company's ongoing Phase 1 breast cancer vaccine and Phase 1 ovarian cancer CAR-T therapy clinical trials, as well as the upcoming Phase 2 breast cancer vaccine clinical trial. Suyasha Gupta is
Dr. Amit Kumar interviewed in latest episode, 'The Vaccine That Could End Breast Cancer' SAN JOSE, Calif., May 6, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, today announced a podcast interview of Anixa Chairman and CEO Dr. Amit Kumar by oncologist Dr. Sanjay Juneja, with more than 500,000 followers through his media brand 'TheOncDoc.' The interview is broadly available on podcast platforms and can be viewed now on YouTube. In the "Target: Cancer
SAN JOSE, Calif., April 18, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, today announced the appointment of Sanjay Juneja, MD to its Cancer Business Advisory Board. Anixa Chairman and CEO Dr. Amit Kumar stated, "Dr. Juneja is an accomplished medical oncologist who has earned status as a top media personality on cancer prevention and treatment innovations. His influence has earned him invitations to help shape healthcare policy, and, most important
SC 13D - Anixa Biosciences Inc (0000715446) (Subject)
SC 13D/A - Anixa Biosciences Inc (0000715446) (Subject)
SC 13D/A - Anixa Biosciences Inc (0000715446) (Subject)
– Antigen-specific T cell responses were observed at all dose levels – – IFNγ and IL-17, immune-mediated biomarkers of T cell activation, increased over time from baseline – – Vaccine was safe and well tolerated – – Conference call to commence today at 6:30 p.m. ET – SAN JOSE, Calif., Dec. 6, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced new and updated positive results from the Phase 1 clinical trial of its breast cancer vaccine. The trial is being conducted in collaboration with Cleveland Clinic with funding by a grant from the U.S. Department of Defense.
– Data to be released at approximately 6:00 p.m. ET, following presentation at 2023 SABCS – – Conference call to commence at 6:30 p.m. ET – SAN JOSE, Calif., Dec. 6, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, will publicly release new data this evening from the ongoing Phase 1 clinical trial of its breast cancer vaccine, which was presented for the first time today at the 2023 San Antonio Breast Cancer Symposium ("SABCS"). All interested parties are invited to join an upcoming conference call today at 6:30 pm ET to discuss the data.